

# CYPROHEPTADINE HYDROCHLORIDE- cyproheptadine hydrochloride solution QUAGEN PHARMACEUTICALS LLC

-----  
**Cyproheptadine Hydrochloride Oral Solution, USP, 2 mg/5 mL**

**Rx only**


## DESCRIPTION

**Each 5 mL (one teaspoonful) contains:** Cyproheptadine Hydrochloride 2 mg

**Inactive Ingredients:** Citric acid, D&C Yellow #10, peppermint flavor, purified water, propylene glycol, sodium citrate, sorbic acid (0.1% as preservative) and sucrose syrup.

**Inactive ingredients for Cyproheptadine Oral Solution (Sugar Free):** alcohol 5% (v/v), butylated hydroxyanisole, citric acid, D&C Yellow #10, peppermint flavor, propylene glycol, purified water, sodium citrate, sorbic acid (0.1%, as preservative), sucralose.

Cyproheptadine HCl is an antihistaminic and antiserotonergic agent. Cyproheptadine hydrochloride is a white to slightly yellowish, crystalline solid, with a molecular weight of 350.89, which is slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform and practically insoluble in ether. It is the sesquihydrate of 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. The molecular formula of the anhydrous salt is  $C_{21}H_{21}N \cdot HCl$  and the structural formula of the anhydrous salt is:



## CLINICAL PHARMACOLOGY

Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites.

**Pharmacokinetics and Metabolism:** After a single 4 mg oral dose of <sup>14</sup>C-labeled cyproheptadine HCl in normal subjects, given as tablets or syrup, 2-20% of the radioactivity was excreted in the stools. Only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. At least 40% of the administered radioactivity was excreted in the urine. No detectable amounts of

unchanged drug were present in the urine of patients on chronic 12-20 mg daily doses of cyproheptadine syrup. The principal metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. Elimination is diminished in renal insufficiency.

## INDICATIONS AND USAGE

Perennial and seasonal allergic rhinitis

Vasomotor rhinitis

Allergic conjunctivitis due to inhalant allergens and foods

Mild, uncomplicated allergic skin manifestations of urticaria and angioedema

Amelioration of allergic reactions to blood or plasma

Cold urticaria

Dermatographism

As therapy for anaphylactic reactions *adjunctive* to epinephrine and other standard measures after the acute manifestations have been controlled.

## CONTRAINDICATIONS

**Newborn or Premature Infants:** This drug should *not* be used in newborn or premature infants.

**Nursing Mothers:** Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

### **Other Conditions:**

Hypersensitivity to cyproheptadine and other drugs of similar chemical structure

Monoamine oxidase inhibitor therapy (see Drug Interactions)

Angle-closure glaucoma

Stenosing peptic ulcer

Symptomatic prostatic hypertrophy

Bladder neck obstruction

Pyloroduodenal obstruction

Elderly, debilitated patients

## WARNINGS

**Children:** Overdosage of antihistamines, particularly in infants and children, may produce hallucinations, central nervous system depression, convulsions and death.

Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation.

**CNS Depressants:** Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.

**Activities Requiring Mental Alertness:** Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.

Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients.

## PRECAUTIONS

**General:** *Cyproheptadine has an atropine-like action and, therefore, should be used with caution in patients with:*

History of bronchial asthma

Increased intraocular pressure

Hyperthyroidism

Cardiovascular disease

Hypertension

**Information for Patients:** Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation. Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.

**Drug Interactions:** MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines. Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long-term carcinogenic studies have not been done with cyproheptadine. Cyproheptadine had no effect on fertility in a two-litter study in rats or a two-generation study in mice at about 10 times the human dose. Cyproheptadine did not produce chromosome damage in human lymphocytes or fibroblasts *in vitro*; high doses ( $10^{-4}$ M) were cytotoxic. Cyproheptadine did not have any mutagenic effect in the Ames microbial mutagen test; concentrations of above 500 mcg/plate inhibited bacterial growth.

**Pregnancy:** Pregnancy Category B. Reproduction studies have been performed in rabbits, mice and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. Cyproheptadine has been shown to be fetotoxic in rats when given by intraperitoneal injection in doses four times the maximum recommended human oral dose. Two studies in pregnant women, however, have not shown that cyproheptadine increases the risk of abnormalities when administered during the first, second and third trimesters of pregnancy. No teratogenic effects were observed in any of the newborns. Nevertheless, because the studies in humans cannot rule out the possibility of harm, cyproheptadine should be used during pregnancy only if clearly needed.

**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from cyproheptadine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see CONTRAINDICATIONS).

**Pediatric Use:** Safety and effectiveness in pediatric patients below the age of two years have not been established. (See CONTRAINDICATIONS, Newborn or Premature Infants, and WARNINGS, Children.)

## **ADVERSE REACTIONS**

Adverse reactions which have been reported with the use of antihistamines are as follows:

**Central Nervous System:** Sedation and sleepiness (often transient), dizziness, disturbed coordination, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, paresthesias, neuritis, convulsions, euphoria, hallucinations, hysteria, faintness.

**Integumentary:** Allergic manifestation of rash and edema, excessive perspiration, urticaria, photosensitivity.

**Special Senses:** Acute labyrinthitis, blurred vision, diplopia, vertigo, tinnitus.

**Cardiovascular:** Hypotension, palpitation, tachycardia, extrasystoles, anaphylactic shock.

**Hematologic:** Hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia.

**Digestive System:** Dryness of mouth, epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation, jaundice.

**Genitourinary:** Urinary frequency, difficult urination, urinary retention, early menses.

**Respiratory:** Dryness of nose and throat, thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.

**Miscellaneous:** Fatigue, chills, headache, increased appetite/weight gain.

To report SUSPECTED ADVERSE REACTIONS, contact Quagen Pharmaceuticals LLC at 1-888-344-9603 or FDA at 1-800-FDA-1088 or [www.FDA.gov/medwatch](http://www.FDA.gov/medwatch).

## **OVERDOSAGE**

Antihistamine overdose reactions may vary from central nervous system depression to stimulation especially in children. Also, atropine-like signs and symptoms (dry mouth; fixed, dilated pupils; flushing, etc.) as well as gastrointestinal symptoms may occur.

*If vomiting has not occurred spontaneously, the patient should be induced to vomit with syrup of ipecac.*

*If the patient is unable to vomit, perform gastric lavage followed by activated charcoal. Isotonic or 1/2 isotonic saline is the lavage of choice. Precautions against aspiration must be taken especially in infants and children. When life-threatening CNS signs and symptoms are present, intravenous physostigmine salicylate may be considered. Dosage and frequency of administration are dependent on age, clinical response and recurrence after response. (See package circulars for physostigmine products.)*

*Saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and,*

therefore, are valuable for their action in rapid dilution of bowel content.

*Stimulants* should *not* be used. Vasopressors may be used to treat hypotension.

The oral LD<sub>50</sub> of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively.

## **DOSAGE AND ADMINISTRATION**

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

Although intended primarily for administration to children, the syrup is also used for administration to adults who cannot swallow tablets.

**Children:** The total daily dosage for children may be calculated on the basis of body weight or body area using approximately 0.25 mg/kg/day (0.11 mg/lb/day) or 8 mg per square meter of body surface (8 mg/m<sup>2</sup>).

*Age 2 to 6 years:* The usual dose is 2 mg (one teaspoonful) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 12 mg a day.

*Age 7 to 14 years:* The usual dose is 4 mg (two teaspoonsful) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 16 mg a day.

**Adults:** The total daily dose for adults should not exceed 0.5 mg/kg/day (0.23 mg/lb/day). The therapeutic range is 4 to 20 mg a day, with the majority of patients requiring 12 to 16 mg a day. An occasional patient may require as much as 32 mg a day for adequate relief. It is suggested that dosage be initiated with 4 mg (two teaspoonsful) three times a day and adjusted according to the size and response of the patient.

## **HOW SUPPLIED**

Cyproheptadine Hydrochloride Oral Solution, USP, 2 mg/5 mL in a yellow, peppermint flavor vehicle, is supplied in a pint (473 mL) container (NDC 70752-101-12) & (NDC 70752-185-12)-Sugar Free

Store at 20°-25°C (68°-77°F) excursion permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP.

Manufactured by:

**Quagen Pharmaceuticals LLC**

West Caldwell, NJ 07006

52001 & 52038

Rev. 02/24

## **PRINCIPAL DISPLAY PANEL**

**NDC 70752-101-12**

**Cyproheptadine  
Hydrochloride Oral**

**Solution, USP**

**2 mg/5 mL**

**473 mL (ONE PINT)**

**Rx only**

**QUAGEN**  
PHARMA

NDC 70752-101-12

**Cyproheptadine  
Hydrochloride  
Oral Solution, USP**

**2 mg/5 mL**

**473 mL (ONE PINT) Rx Only**

**Each 5 mL (one teaspoonful) contains:**  
Cyproheptadine Hydrochloride 2 mg, Sorbic Acid 0.1%  
added as preservative.

**Usual Dosage:** See accompanying package insert.

**Store at 20°-25°C (68°-77°F) excursion permitted  
to 15°-30°C (59°-86°F) [See USP Controlled Room  
Temperature].**

Dispense in a tight, light-resistant container as defined  
in the USP.

**Manufactured by:**  
Quagen Pharmaceuticals LLC  
West Caldwell, NJ 07006

  
**MADE IN USA**

50004 Rev. 03/21

GTIN 00370752101127



N 3 70752-10112 7

**1" X 3"  
NON  
VARNISH  
AREA**

**PRINCIPAL DISPLAY PANEL**

**NDC 70752-185-12**

**Cyproheptadine  
Hydrochloride  
Oral Solution, USP**

**2 mg/5 mL**

**Sugar Free**

**473 mL**

**Rx only**



NDC 70752-185-12

# Cyproheptadine Hydrochloride Oral Solution, USP

2 mg/5 mL

Each 5 mL (one teaspoonful) contains: Cyproheptadine Hydrochloride 2 mg, Alcohol 5%, Sorbic Acid 0.1% added as preservative.

**Usual Dosage:** See accompanying package insert.

**Store at 20°-25°C (68°-77°F) excursion permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].**

Dispense in a tight, light-resistant container as defined in the USP.

**Manufactured by:**  
Quagen Pharmaceuticals LLC  
West Caldwell, NJ 07006

50107  
Rev. 03/24



GTIN 00370752185127



N 3 70752-18512 7



NDC 70752-185-12

# Cyproheptadine Hydrochloride Oral Solution, USP

2 mg/5 mL

Sugar Free

16 fl oz (473 mL)

Rx Only

1.0" X 2.3"  
NON VARNISH  
AREA

## CYPROHEPTADINE HYDROCHLORIDE

cyproheptadine hydrochloride solution

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:70752-101
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
CYPROHEPTADINE HYDROCHLORIDE (UNII: NJ82J0F8QC) (CYPROHEPTADINE - UNII:2YHB6175DO)	CYPROHEPTADINE HYDROCHLORIDE	2 mg in 5 mL

## Inactive Ingredients

Ingredient Name	Strength
<b>ANHYDROUS CITRIC ACID</b> (UNII: XF417D3PSL)	
<b>D&amp;C YELLOW NO. 10</b> (UNII: 35SW5USQ3G)	
<b>WATER</b> (UNII: 059QF0KO0R)	
<b>PROPYLENE GLYCOL</b> (UNII: 6DC9Q167V3)	
<b>TRISODIUM CITRATE DIHYDRATE</b> (UNII: B22547B95K)	
<b>SORBIC ACID</b> (UNII: X045WJ989B)	
<b>SUCROSE</b> (UNII: C151H8M554)	
<b>PEPPERMINT</b> (UNII: V95R5KMY2B)	

## Product Characteristics

<b>Color</b>		<b>Score</b>	
<b>Shape</b>		<b>Size</b>	
<b>Flavor</b>	PEPPERMINT	<b>Imprint Code</b>	
<b>Contains</b>			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70752-101-12	473 mL in 1 BOTTLE, GLASS; Type 0: Not a Combination Product	05/22/2019	

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA212423	05/22/2019	

## CYPROHEPTADINE HYDROCHLORIDE

cyproheptadine hydrochloride solution

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:70752-185
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>CYPROHEPTADINE HYDROCHLORIDE</b> (UNII: NJ82J0F8QC) (CYPROHEPTADINE - UNII:2YHB6175DO)	CYPROHEPTADINE HYDROCHLORIDE	2 mg in 5 mL

Inactive Ingredients	
Ingredient Name	Strength
ALCOHOL (UNII: 3K9958V90M)	
ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)	
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)	
WATER (UNII: 059QF0KO0R)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)	
SORBIC ACID (UNII: X045WJ989B)	
SUCRALOSE (UNII: 96K6UQ3ZD4)	
PEPPERMINT (UNII: V95R5KMY2B)	
BUTYLATED HYDROXYANISOLE (UNII: REK4960K2U)	

Product Characteristics			
Color		Score	
Shape		Size	
Flavor	PEPPERMINT	Imprint Code	
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70752-185-12	473 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	12/22/2023	

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA212423	12/22/2023	

**Labeler** - QUAGEN PHARMACEUTICALS LLC (073645339)

**Registrant** - QUAGEN PHARMACEUTICALS LLC (073645339)

Establishment			
Name	Address	ID/FEI	Business Operations
QUAGEN PHARMACEUTICALS LLC		080281331	MANUFACTURE(70752-101, 70752-185) , pack(70752-101, 70752-185)